Global Next Generation Sequencing Market is valued at USD 8156.4 Million in 2020 and is expected to reach USD 26762.5 Million by 2027 with a CAGR of 18.5% over the forecast period.
Global Next-Generation Sequencing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Increasing number of cancer patients and growing research and development in this field are the significant factors that are driving the growth of the Global Next Generation Sequencing Market.
Next-generation sequencing (NGS) is any of several high throughput approaches of DNA sequencing using the concept of massively parallel processing. Many NGS platforms differ on the basis of engineering configurations and sequencing chemistry. They share the technical paradigm of massively parallel sequencing via spatially separated, clonally amplified DNA templates or single DNA molecules in a flow cell. NGS is also known as capillary sequencing, massively parallel sequencing or massively parallel sequencing. Next-generation sequencing technologies are currently used for whole-genome sequencing, investigation of genome diversity, epigenetic, metagenomics, identification of non-coding RNAs and protein binding sites, and gene expression profiling by RNA sequencing.
These are also used in microbiology and virology for detecting various microorganisms and viruses by using metagenomic approaches, investigating microbial communities in the human bodies and environment. And, it is also used for the analysis of viral genome variability within the host and detection of low abundance antiviral drug resistance mutations in HIV patients. Some of these sequencing technologies emerged in 1994-1998 and have been commercially available since 2005.
The COVID-19 outbreak has had a positive impact on the next-generation sequencing (NGS) market. Various major players and new startups in the NGO market have come forward to support the research on testing kits, vaccines, and treatment for affected patients as play an important role in the clinical labs and research to fight against the SARS-CoV-2, which results in the COVID-19. Thus, the COVID-19 has overall shown a positive impact on the growth of the NGS market.
Global next-generation sequencing market report covers prominent players are Thermo Fisher Scientific, Illumina, PerkinElmer, BGI Group, Agilent Technologies, Bio-Rad Laboratories, Eurofins GATC Biotech GmbH, DNASTAR lnc., Genomatrix GmbH, Oxford Nanopore Technologies, F. Hoffman-La Roche Ltd., QIAGEN, and others.
The next-generation sequencing market is divided into types of sequencing, product type, technology, application, end-user, and region & country level. Based on types of sequencing, the global next-generation sequencing market is segmented into whole-genome sequencing, targeted resequencing and whole-exome sequencing. Based on product type, the market is divided into consumables, platforms and services. And based on technology, the market is segmented into sequencing by synthesis, ION semiconductor sequencing, nanopore sequencing, single-molecule real-time sequencing and other technologies. On the basis of application, the market is divided into diagnostics, drug discovery, agricultural and animal research and others. Based on end-user, the market is segmented into academic institutes, research centers, pharmaceuticals and biotechnology industries, hospitals and clinics, and others.
News:
Ancestry Launched New Next Generation Sequencing Tool
On August 5th, 2020; Consumer genomic company Ancestry launched a new product –dubbed Ancestry Health powered by NGS. This product will screen users for the genes associated with breast cancer, colon cancer, blood disorders and heart diseases. The service was developed by Quest Diagnostics and price of it is $179. This tool can examine harder-to-sequence variants of the human genome than traditional microarray tech. Now, consumers are spending less on nonessential items – so, the hefty price tags of DTC genetic tests will likely drive consumers further away from these products. This tool could help patients cut back on meteoric costs associated with chronic illness by allowing for earlier intervention.
Increasing cancer patients globally is one of the major factors driving the growth of the global next-generation sequencing market. For instance; according to World Health Organization Report on Cancer (WHO) 2020, in 2018, 18.1 million people around the world suffered with cancer and 9.6 million died due to this cancer-like chronic disease. The most frequently diagnosed cancer is lung cancer about 11.6% of all cases followed by female breast cancer 11.6% and colorectal cancers around 10.2 %. Lung cancer is the leading cause of most of the deaths occurred by cancer. Deaths are due to colorectal and stomach cancers followed by lung cancer. Next-generation sequencing is used to identify novel and rare cancer mutations and to detect familial cancer mutation carriers and to provide a molecular rationale for appropriate targeted therapy.
In addition, the growing, rising number of research and development activities in the field of NGS and growing cases of Covid-19 globally are also fostering the growth of the next-generation sequencing (NGS) market. For instance; in 2021, Cebra Research launched two new PCR-based and NGS-based exploratory tools for viral diseases to support R&D in for vaccine development against infectious diseases. WGS of respiratory viruses and SARS-CoV-2 is made easier using the NGS-based test. Also in 2020, Eurofins Genomics launched cost-effective, optimized, SARS-CoV-2 NGS services that offer to the sequence of complete viral genomes. In May 2020, The KAPA Target Enrichment portfolio was launched by Roche for target enrichment during sequencing. In February 2021, Oxford Nanopore Technologies deployed 200 MinIONs to China for use viral and bacterial sequencing surveillance programs. Increase in research in NGS promoting other advanced researches and methodologies in the NGS. Furthermore, low cost of NGS and supportive government policies are some other factors supplementing the market growth.
However, high investment in research and development may limit market growth. In spite of that, its increasing applications in chronic diseases may offer an the opportunity for the further growth of the next-generation sequencing market.
Geographically, North America is expected to dominate the global next-generation sequencing market over the forecast period due to the increasing number of FDA approvals, the presence of key players, and the rising number of cancer patients in this region. For instance; according to npj Genomic Medicine; in April 2018, Food and Drug Administration (FDA) finalized a guidance document for design, development and analytical validation of NGS based on Vitro Diagnostics (IVDs). This is for diagnosis of suspected germline diseases, in efforts to establish of regulatory approach for next generation sequencing testing. Also in 2018, FDA granted marketing approval for ClonoSEQ assay, a NGS based diagnostic test for MRD (Minimal Residual Disease) in patients having acute lymphoblastic leukemia (ALL) or multiple myeloma. In addition, increasing number of cancer patients in this region is also fostering the demand for next-generation sequencing technology. According to American Cancer Society 2019, more than 1.7 million cancer cases were detected in U.S. About 606,880 Americans were expected to die of cancer in 2019.
Asia Pacific is expected to grow faster in this market due to increasing prevalence of genetic disorders, increasing research & development and rising awareness about genetic health. For instance; according to Indian Council of Medical Research (ICMR), about 70 million Indians suffer from inherited genetic diseases or rare diseases (RD). These include hemophilia, thalassemia, sickle cell anemia, retinal dystrophies, primary immunodeficiency (PID), haemangioma, cystic fibrosis etc. As NGS reduce both cost and time required for exome or genome analysis and NGS is allowed for the implementation of panels of genes for diagnosis and research in genetic disorders.
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Interested in this report?
Next-Generation Sequencing Market Size, Share & Trends Analysis Report By Type of Sequencing (Whole Genome Sequencing, Targeted Resequencing, Whole Exome Sequencing), By Product Type (Consumables, Platforms, Services), By Technology (Sequencing by Synthesis, ION Semiconductor Sequencing, Nanopore Sequencing, Single-Molecule Real-Time Sequencing, Other Technologies) Based On Region, And Segment Forecasts, 2022 - 2028